NO315842B1 - Anvendelse av hyaluronsyre for fremstilling av en farmasöytisk blanding - Google Patents
Anvendelse av hyaluronsyre for fremstilling av en farmasöytisk blanding Download PDFInfo
- Publication number
- NO315842B1 NO315842B1 NO19973732A NO973732A NO315842B1 NO 315842 B1 NO315842 B1 NO 315842B1 NO 19973732 A NO19973732 A NO 19973732A NO 973732 A NO973732 A NO 973732A NO 315842 B1 NO315842 B1 NO 315842B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- dalton
- molecular weight
- interstitial cystitis
- urinary bladder
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 114
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 113
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000003932 urinary bladder Anatomy 0.000 claims abstract description 85
- 238000011282 treatment Methods 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 14
- 210000003708 urethra Anatomy 0.000 claims description 9
- 210000000626 ureter Anatomy 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 210000000244 kidney pelvis Anatomy 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 230000007794 irritation Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract description 60
- 238000000034 method Methods 0.000 abstract description 20
- 241000124008 Mammalia Species 0.000 abstract description 16
- 210000003741 urothelium Anatomy 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 description 55
- 239000000243 solution Substances 0.000 description 31
- 230000036407 pain Effects 0.000 description 27
- 230000004044 response Effects 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 230000006872 improvement Effects 0.000 description 20
- 229940043138 pentosan polysulfate Drugs 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 206010027566 Micturition urgency Diseases 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 description 8
- 201000003146 cystitis Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 206010005052 Bladder irritation Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910001868 water Inorganic materials 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 230000000964 angiostatic effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011418 maintenance treatment Methods 0.000 description 4
- 210000003689 pubic bone Anatomy 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 201000007031 bladder benign neoplasm Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- SNXUWJAFSLKIMF-UHFFFAOYSA-M sodium;hypochlorous acid;4-tetradecylbenzenesulfonate Chemical compound [Na+].ClO.CCCCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 SNXUWJAFSLKIMF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010057687 Bloody discharge Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000201841 Celosia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010069645 Reduced bladder capacity Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 208000028484 Urethral disease Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- VSBFNCXKYIEYIS-UHFFFAOYSA-N Xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000563 bladder tuberculosis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960001516 silver nitrate Drugs 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000010585 urethral diverticulum Diseases 0.000 description 1
- 239000000083 urinary anti-infective agent Substances 0.000 description 1
- 208000011805 urinary bladder tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/388,038 US5591724A (en) | 1995-02-14 | 1995-02-14 | Method for treating the urinary bladder and associated structures using hyaluronic acid |
| US59101596A | 1996-02-08 | 1996-02-08 | |
| PCT/CA1996/000094 WO1996025168A1 (en) | 1995-02-14 | 1996-02-14 | Use of hyaluronic acid for the treatment of interstitial cystitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973732D0 NO973732D0 (no) | 1997-08-13 |
| NO973732L NO973732L (no) | 1997-10-10 |
| NO315842B1 true NO315842B1 (no) | 2003-11-03 |
Family
ID=27012116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973732A NO315842B1 (no) | 1995-02-14 | 1997-08-13 | Anvendelse av hyaluronsyre for fremstilling av en farmasöytisk blanding |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5888986A (enEXAMPLES) |
| EP (1) | EP0813417B1 (enEXAMPLES) |
| JP (1) | JP4354528B2 (enEXAMPLES) |
| KR (1) | KR100268660B1 (enEXAMPLES) |
| CN (1) | CN1181016A (enEXAMPLES) |
| AT (1) | ATE247476T1 (enEXAMPLES) |
| AU (1) | AU705289B2 (enEXAMPLES) |
| BR (1) | BR9607601A (enEXAMPLES) |
| CA (1) | CA2203621C (enEXAMPLES) |
| CZ (1) | CZ288218B6 (enEXAMPLES) |
| DE (1) | DE69629553T2 (enEXAMPLES) |
| DK (1) | DK0813417T3 (enEXAMPLES) |
| ES (1) | ES2205013T3 (enEXAMPLES) |
| HU (1) | HUP9800467A3 (enEXAMPLES) |
| IN (1) | IN181358B (enEXAMPLES) |
| NO (1) | NO315842B1 (enEXAMPLES) |
| NZ (1) | NZ300903A (enEXAMPLES) |
| PT (1) | PT813417E (enEXAMPLES) |
| TR (1) | TR199700782T1 (enEXAMPLES) |
| WO (1) | WO1996025168A1 (enEXAMPLES) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0952855B1 (en) | 1991-07-03 | 2005-07-27 | Meditech Research Limited | Use of hyaluronan in gene therapy |
| US6232301B1 (en) | 1996-12-27 | 2001-05-15 | Seikagaku Corporation | Remedies for bladder disorders |
| US6548487B2 (en) | 1996-12-27 | 2003-04-15 | Seikagaku Corporation | Agent for treatment of bladder troubles |
| ATE264674T1 (de) * | 1998-10-22 | 2004-05-15 | Bioniche Life Sciences Inc | Verwendung von hyaluronsäure zur behandlung der bestrahlungs-blasenentzündung |
| US6083933A (en) * | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
| CZ20022372A3 (cs) * | 1999-12-13 | 2002-11-13 | Bioniche Life Sciences Inc. | Terapeuticky pouľitelné syntetické oligonukleotidy |
| CA2395493C (en) * | 1999-12-28 | 2010-06-22 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| US7504387B2 (en) * | 2002-10-16 | 2009-03-17 | Arthrodynamic Technologies, Animal Health Division, Inc. | Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis |
| US20040161476A1 (en) | 2003-02-19 | 2004-08-19 | Hahn Sungtack Samuel | Cystitis treatment with high dose chondroitin sulfate |
| RU2270678C1 (ru) * | 2004-06-30 | 2006-02-27 | Государственное образовательное учреждение высшего профессионального образования Российский государственный медицинский университет Министерства здравоохранения Российской Федерации | Способ лечения хронического цистита у детей |
| AU2006204769A1 (en) * | 2005-01-14 | 2006-07-20 | Urigen, Inc. | Kits and improved compositions for treating lower urinary tract |
| DE102006060953A1 (de) | 2006-12-12 | 2008-08-07 | Farco-Pharma Gmbh | Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes |
| US8343942B2 (en) * | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
| TWI383796B (zh) | 2009-08-14 | 2013-02-01 | Holy Stone Healthcare Co Ltd | Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer |
| TWI516269B (zh) | 2009-08-14 | 2016-01-11 | 禾伸堂生技股份有限公司 | 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物 |
| HUP0900717A3 (en) | 2009-11-18 | 2012-02-28 | Richter Gedeon Nyrt | Pharmaceutical composition for urological use containing zinc hyaluronate |
| US8575130B2 (en) * | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| US8722644B2 (en) | 2010-01-04 | 2014-05-13 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer |
| US20110166098A1 (en) * | 2010-01-04 | 2011-07-07 | Wu Tsung-Chung | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| US8449512B2 (en) | 2010-04-09 | 2013-05-28 | Davinci Biomedical Research Products Inc. | Stoma stabilitating device and method |
| US9029347B2 (en) | 2010-08-05 | 2015-05-12 | Holy Stone Healthcare Co., Ltd. | Method and mixture for treating and preventing inflammatory bowel disease |
| EP2545925B1 (en) | 2011-07-12 | 2018-02-14 | Holy Stone Healthcare Co.,Ltd. | Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases |
| ITMI20111732A1 (it) * | 2011-09-27 | 2013-03-28 | Bsdpharma Srl | Formulazioni farmaceutiche per la riduzione della sensibilizzazione crociata tra colon-retto ed il distretto urogenitale con mezzi non-farmacologici. |
| RU2519010C1 (ru) * | 2013-03-20 | 2014-06-10 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Композиция для лечения цистита |
| WO2015018461A1 (fr) | 2013-08-09 | 2015-02-12 | Genbiotech | Compositions therapeutiques comprenant d'acide hyaluronique |
| CN103655601B (zh) * | 2013-12-31 | 2019-10-25 | 上海建华精细生物制品有限公司 | 一种用于膀胱灌洗的组合物 |
| CN103861091B (zh) * | 2014-03-20 | 2016-04-27 | 辽宁亿灵科创生物医药科技有限公司 | 治疗膀胱炎的药物组合物 |
| US20160045623A1 (en) | 2015-04-03 | 2016-02-18 | Lipella Pharmaceuticals, Inc. | Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI) |
| WO2015154007A1 (en) * | 2014-04-03 | 2015-10-08 | Lipella Pharmaceuticals, Inc. | Systems and methods of detecting interstitial cystitis |
| RU2557949C1 (ru) * | 2014-08-14 | 2015-07-27 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Способ лечения лучевого и интерстициального цистита |
| GB201616838D0 (en) * | 2016-10-04 | 2016-11-16 | Nat Univ Ireland | Hyaluronan compositions, and uses thereof in treatment of interstitial cystitis |
| EP3400951B1 (de) * | 2017-05-12 | 2019-12-11 | Farco-Pharma GmbH | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis |
| IT201900019762A1 (it) * | 2019-10-24 | 2021-04-24 | Fidia Farm Spa | Composizione farmaceutica per uso nel trattamento della cistite di varia eziologia |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4296104A (en) * | 1979-08-30 | 1981-10-20 | Herschler R J | Therapeutic dimethyl sulfoxide composition and methods of use |
| US4302577A (en) * | 1979-10-05 | 1981-11-24 | Biomed Research Inc. | Process for preparing CSA or CSC |
| US5180715A (en) * | 1980-11-17 | 1993-01-19 | The Regents Of The University Of California | Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate |
| DE3118588C2 (de) * | 1981-05-11 | 1983-07-07 | Luitpold-Werk, Chemisch-Pharmazeutische Fabrik, 8000 München | Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung |
| US4640912A (en) * | 1983-06-09 | 1987-02-03 | Hausman Marvin S | Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans |
| US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
| US4966890A (en) * | 1986-04-04 | 1990-10-30 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
| US4820693A (en) * | 1986-05-22 | 1989-04-11 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
| US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
| US5037810A (en) * | 1987-03-17 | 1991-08-06 | Saliba Jr Michael J | Medical application for heparin and related molecules |
| ES2150427T3 (es) * | 1992-06-02 | 2000-12-01 | Bard Inc C R | Procedimiento y dispositivo de implante para el suministro de farmacos a largo plazo. |
| DE784487T1 (de) * | 1993-03-19 | 1999-11-04 | Q-Med Ab, Uppsala | Ein präparat und ein verfahren zur gewebevermehrung |
-
1996
- 1996-02-13 IN IN262CA1996 patent/IN181358B/en unknown
- 1996-02-14 NZ NZ300903A patent/NZ300903A/xx not_active IP Right Cessation
- 1996-02-14 EP EP96901681A patent/EP0813417B1/en not_active Expired - Lifetime
- 1996-02-14 ES ES96901681T patent/ES2205013T3/es not_active Expired - Lifetime
- 1996-02-14 TR TR97/00782T patent/TR199700782T1/xx unknown
- 1996-02-14 AU AU46179/96A patent/AU705289B2/en not_active Expired
- 1996-02-14 WO PCT/CA1996/000094 patent/WO1996025168A1/en active IP Right Grant
- 1996-02-14 PT PT96901681T patent/PT813417E/pt unknown
- 1996-02-14 AT AT96901681T patent/ATE247476T1/de active
- 1996-02-14 JP JP52454596A patent/JP4354528B2/ja not_active Expired - Lifetime
- 1996-02-14 CN CN96192529A patent/CN1181016A/zh active Pending
- 1996-02-14 CA CA002203621A patent/CA2203621C/en not_active Expired - Lifetime
- 1996-02-14 HU HU9800467A patent/HUP9800467A3/hu unknown
- 1996-02-14 DE DE69629553T patent/DE69629553T2/de not_active Expired - Lifetime
- 1996-02-14 DK DK96901681T patent/DK0813417T3/da active
- 1996-02-14 BR BR9607601-1A patent/BR9607601A/pt not_active Application Discontinuation
- 1996-02-14 KR KR1019970705648A patent/KR100268660B1/ko not_active Expired - Fee Related
- 1996-02-14 CZ CZ19972574A patent/CZ288218B6/cs not_active IP Right Cessation
- 1996-05-13 US US08/644,438 patent/US5888986A/en not_active Expired - Lifetime
-
1997
- 1997-08-13 NO NO19973732A patent/NO315842B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ300903A (en) | 1999-07-29 |
| ATE247476T1 (de) | 2003-09-15 |
| PT813417E (pt) | 2003-12-31 |
| US5888986A (en) | 1999-03-30 |
| CZ288218B6 (en) | 2001-05-16 |
| AU4617996A (en) | 1996-09-04 |
| JP4354528B2 (ja) | 2009-10-28 |
| KR100268660B1 (ko) | 2000-10-16 |
| BR9607601A (pt) | 1999-09-14 |
| CZ257497A3 (cs) | 1998-01-14 |
| CA2203621C (en) | 1998-04-28 |
| CN1181016A (zh) | 1998-05-06 |
| EP0813417A1 (en) | 1997-12-29 |
| DK0813417T3 (da) | 2003-11-03 |
| NO973732D0 (no) | 1997-08-13 |
| DE69629553D1 (de) | 2003-09-25 |
| EP0813417B1 (en) | 2003-08-20 |
| CA2203621A1 (en) | 1996-08-22 |
| NO973732L (no) | 1997-10-10 |
| IN181358B (enEXAMPLES) | 1998-05-30 |
| HUP9800467A3 (en) | 1999-01-28 |
| WO1996025168A1 (en) | 1996-08-22 |
| KR19980702251A (ko) | 1998-07-15 |
| TR199700782T1 (xx) | 1998-03-21 |
| HUP9800467A2 (hu) | 1998-06-29 |
| ES2205013T3 (es) | 2004-05-01 |
| AU705289B2 (en) | 1999-05-20 |
| JPH10513476A (ja) | 1998-12-22 |
| MX9706182A (es) | 1998-07-31 |
| DE69629553T2 (de) | 2004-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO315842B1 (no) | Anvendelse av hyaluronsyre for fremstilling av en farmasöytisk blanding | |
| AU753124B2 (en) | Dextran formulations and method for treatment of inflammatory joint disorders | |
| JPH068323B2 (ja) | ヒアルロン酸薬理活性画分、その製造方法および医薬組成物 | |
| US5880108A (en) | Method for treating the internal urinary bladder and associated structures using hyaluronic acid | |
| US5591724A (en) | Method for treating the urinary bladder and associated structures using hyaluronic acid | |
| CN118902992A (zh) | 一种含有小分子透明质酸的注射液的用途 | |
| US11826380B2 (en) | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments | |
| KR20200004833A (ko) | 방광염을 치료하기 위해 저장 안정성이 증가된, 콘드로이틴 설페이트 (20 mg/ml), 히알루론산 (16 mg/ml) 및 포스페이트 버퍼 (ph 6.1 내지 7.9)를 함유하며 방광 점적 주입 조성물 | |
| JP5788896B2 (ja) | 膀胱疾患の治療のための医薬組成物 | |
| KR20200003015A (ko) | 방광염의 치료를 위해 증가된 저장 안정성을 갖고 콘드로이틴 설페이트 (4.5 mg/ml), 히알루론산 (16 mg/ml) 및 포스페이트 버퍼 (ph 6.1 내지 7.9)를 함유하는 방광 점적 주입 조성물 | |
| MXPA97006182A (es) | Uso de acido hialuronico para el tratamiento de cistitis intersticial | |
| CA2167044C (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| Marchuk | Treatment peculiarities of transient synovitis in children | |
| EP3496731B1 (en) | Composition for the treatment of pathologies of the urinary system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |